Trial Summary
What is the purpose of this trial?This study is being done to examine whether transcranial direct current stimulation (tDCS) will increase cerebral blood flow which may provide a clinical benefit such as improving cognitive impairment.
Eligibility Criteria
This trial is for individuals with conditions like Moyamoya Syndrome and various forms of cerebral atherosclerosis, which affect blood flow to the brain. Participants should be experiencing cognitive impairment due to these conditions.Inclusion Criteria
My scans show reduced blood flow due to blood vessel issues.
I have trouble with memory or thinking clearly.
Exclusion Criteria
Pregnancy
Contraindication to MRI or tDCS including metallic implanted objects
Medical instability or inability to cooperate during the study as assessed by the treating physician to participate in the study.
Participant Groups
The study tests if using transcranial direct current stimulation (tDCS), specifically Soterix® devices, can boost blood flow in the brain and improve thinking skills affected by chronic hypoperfusion.
6Treatment groups
Experimental Treatment
Group I: Phase II Sham Stimulation, Then Active StimulationExperimental Treatment2 Interventions
Subjects first receive sham tDCS plus cognitive training daily for 10 days. After a washout period of 4 weeks, they will perform at-home active tDCS plus cognitive training daily for 10 days.
Group II: Phase II Active Stimulation, Then Sham StimulationExperimental Treatment2 Interventions
Subjects first receive active tDCS plus cognitive training every weekday for 10 days. After washout period of 4 weeks, they will perform at-home sham tDCS plus cognitive training every weekday for 10 days.
Group III: Phase I Disease Group: Sham Stimulation, Then Active StimulationExperimental Treatment1 Intervention
Subject diagnosed with Moyamoya disease or severe extracranial atherosclerotic disease will receive sham stimulation concurrently with MRI CBF imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive 20 minutes of 2 mA tDCS concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
Group IV: Phase I Disease Group: Active Stimulation, Then Sham StimulationExperimental Treatment1 Intervention
Subject diagnosed with Moyamoya disease or severe extracranial atherosclerotic disease will receive 20 minutes of 2 mA tDCS concurrently with MRI cerebral blood flow (CBF) imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive sham stimulation concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
Group V: Phase I - Health Volunteer Group: Sham Stimulation, Then Active StimulationExperimental Treatment1 Intervention
Healthy subjects will receive sham stimulation concurrently with MRI CBF imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive 20 minutes of 2 mA tDCS concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
Group VI: Phase I - Health Volunteer Group: Active Stimulation, Then Sham StimulationExperimental Treatment1 Intervention
Healthy subjects will receive 20 minutes of 2 mA tDCS concurrently with MRI cerebral blood flow (CBF) imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive sham stimulation concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo Clinic in RochesterRochester, MN
Loading ...
Who Is Running the Clinical Trial?
Mayo ClinicLead Sponsor